Everlywell and Jona announced a partnership to expand access to Jona’s gut microbiome test through Everlywell’s consumer platform. The deal is positioned as a distribution expansion, moving microbiome testing into a broader set of consumers via an established at-home testing channel. While the excerpt focuses on access rather than clinical validation details, the arrangement signals continued commercial interest in microbiome analytics and consumer-facing diagnostics, where companies compete on test availability, user experience, and downstream data interpretation services. For biotech industry stakeholders, this is a reminder that microbiome programs are increasingly paired with scalable distribution strategies, not just scientific discovery.